top of page
The Professional Network for Healthcare Experts
EU approves Etcamah and advances Enhertu combination for biomarker-defined breast cancers
The two regulatory decisions could expand first-line treatment options for patients with ESR1-mutant ER-positive disease and HER2-positive metastatic breast cancer, although Enhertu still requires European Commission approval.
nuaxia
Jul 312 min read
CHMP backs Trodelvy plus Keytruda for first-line PD-L1-positive metastatic breast cancer
If authorised, the combination would add an antibody-drug conjugate-based first-line option for eligible European patients with unresectable locally advanced or metastatic triple-negative breast cancer.
nuaxia
Jul 272 min read
FDA Approves Celcuity’s Revtorpyk for PI3K-Pathway Targeted Breast Cancer Treatment
The approval of Revtorpyk (gedatolisib) gives Celcuity a new treatment option for HR-positive, HER2-negative breast cancer patients without PIK3CA mutations, following positive Phase III VIKTORIA-1 data showing improved progression-free survival.
nuaxia
Jul 153 min read
Roche Strengthens Breast Cancer Pipeline with $490m+ Astex Partnership
Genentech has secured global rights to a fragment-based drug discovery programme targeting a key regulator of breast cancer cell growth.
nuaxia
Jul 72 min read
bottom of page